You are here

  • Home
  • Archive
  • Volume 10, Issue 8
  • Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Nguyen S, Chevalier MF, Benmerzoug S, et al
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments
Journal for ImmunoTherapy of Cancer 2022;10:e004880. doi: 10.1136/jitc-2022-004880